Boston Scientific stock steadies after FDA flags AXIOS stent issue; Penumbra deal still in play
The FDA linked Boston Scientific’s AXIOS stent delivery systems to 167 serious injuries and three deaths, urging an immediate halt in use. Shares traded near $91.20 midday Wednesday, little changed as investors weighed the safety warning and the pending $14.5 billion Penumbra acquisition.